Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Tero-Pekka Alastalo, MD, PhD
President, Chief Medical Officer

European Entrepreneurship & Innovation
Stanford School of En...
•  We are a genetic diagnostics company founded in Helsinki, Finland
•  Proprietary NGS sequencing method, OS-Seq, develop...
OS-SeqTM Technology
hybrid selection and enrichment on flow cell
SEQUENCING
LIBRARY
RANDOM SHEARING
Day	
  1	
  
TARGET
ENR...
Illumina(TruSight BpG(OS3Seq BpG(PCR3free(OS3Seq
Manual&steps 15 7 5
Hands0on&time 4h&45min 1h&45min 1h&15min
Total&time 5...
A Top Product with Lowest COGS
5
Developed in
Stanford and
published in
Nature, our OS-
Seq method
provides extreme
efficie...
Our Process
6
A physician
sends us a
sample
We sequence
the DNA with
our cost efficient
OS-Seq method
yielding high
coverag...
Solving the Problems
7
Customers are 
frustrated:
Solving all of these
problems is a revolution:
Difficult to
communicate w...
142 Hospitals in 18 Countries
Over 4000 disease with known
molecular genetic background, >36
million patients in Europe
Cancer diagnostics and targeted
...
We Are in a Unique Position For Growth in
an Exploding Market
10
NGS
in inherited 
disorders 
grows to a 
$1.5Bn market 
b...
THANK YOU!
11
Tero-Pekka Alastalo, President
+1 650 285 8564
tpa@blueprintgenetics.com
953 Indiana Street, QB3@953
CA 9410...
Upcoming SlideShare
Loading in …5
×

Tero-Pekka Alastalo - Blueprint Genetics - Stanford Engineering - Jan 4 2016

2,094 views

Published on

Talk by Tero-Pekka Alastalo, CEO - Blueprint Genetics (FI), at Stanford on Jan 4 2016, in our session on 'European Startup Bridges in Silicon Valley'.

Website: http://www.StanfordEuropreneurs.org
YouTube Channel: https://www.youtube.com/user/StanfordEuropreneurs
Twitter: @Europreneurs

Published in: Technology
  • Be the first to comment

Tero-Pekka Alastalo - Blueprint Genetics - Stanford Engineering - Jan 4 2016

  1. 1. Tero-Pekka Alastalo, MD, PhD President, Chief Medical Officer European Entrepreneurship & Innovation Stanford School of Engineering 4 Jan 2016 http://blueprintgenetics.com
  2. 2. •  We are a genetic diagnostics company founded in Helsinki, Finland •  Proprietary NGS sequencing method, OS-Seq, developed at Stanford University by a Finnish DNA biologists Samuel Myllykangas, published in Nature Biotechnology •  OS-Seq represents the most effective targeted sequencing technology in the market – developed for medical applications Background 2 Stanford University Oligonucleotid- selective sequencing OS-Seq™ Nature Biotechnology 2011
  3. 3. OS-SeqTM Technology hybrid selection and enrichment on flow cell SEQUENCING LIBRARY RANDOM SHEARING Day  1   TARGET ENRICHMENT and SEQUENCING SEQUENCING  LIBRARY Target enrichment on flow cell Sequencing on Illumina system Sequencing library Oligonucleotide library PREPARATION Capture of genomic targets in situ Flow cell Fully integrated target enrichment and sequencing PROCESSING SEQUENCING Days 1 - 3
  4. 4. Illumina(TruSight BpG(OS3Seq BpG(PCR3free(OS3Seq Manual&steps 15 7 5 Hands0on&time 4h&45min 1h&45min 1h&15min Total&time 52h 5h&45&min 4h Illumina(TruSight BpG(OS3Seq BpG(PCR3free(OS3Seq Reaction(set3up Fragmentation Tagmentation End(repair(and(A3tailing Clean3up Ligation PCR Hybridization Pull3down DAY$2 DAY$3DAY$1 •  OS-Seq has 63% (with PCR) or 74% (PCR-free) faster hands-on time •  OS-Seq has 89% (with PCR) or 92% (PCR-free) faster total time Workflow
  5. 5. A Top Product with Lowest COGS 5 Developed in Stanford and published in Nature, our OS- Seq method provides extreme efficiency for sequencing World’s first IBM Watson-platform for inherited disorders takes the clinical interpretation of data to a next level We have industry’s lowest COGS >60% SAVINGS** 60-80% LESS LAB WORK** ** Compared to Illumina TruSight High reliability data with 99-100% coverage
  6. 6. Our Process 6 A physician sends us a sample We sequence the DNA with our cost efficient OS-Seq method yielding high coverage We interpret the the data clinically with our IBM Watson based big data platform We send a report online and get a payment SAMPLE SEQUENCING ANALYSIS REPORT
  7. 7. Solving the Problems 7 Customers are frustrated: Solving all of these problems is a revolution: Difficult to communicate with testing laboratory High non-transparent pricing; Unclear billing policies Turnaround times are too long Diagnostic yield is poor, too many false negatives due to small panels and low sequencing coverage We focus highly on clinical specialties, our geneticists provide clinical support in the report Due to extremely low production cost we are able to lead price development and have an aggressive Max-out-of-pocket policy We run a turnaround time of 3 weeks, not several months We have the best diagnostic yield in the market due to comprehensive panels and high sequencing coverage Fast lead time 21 DAYS Coverage 100% Starting at $1500 Gapless panels fully cover target genes Genetic diagnostics with unbeatable turn-around time New technology and innovations allow remarkable cost- efficiency
  8. 8. 142 Hospitals in 18 Countries
  9. 9. Over 4000 disease with known molecular genetic background, >36 million patients in Europe Cancer diagnostics and targeted treatment Pharmacogenomics – essential tool for todays’s drug development Genetics Is Changing Medicine
  10. 10. We Are in a Unique Position For Growth in an Exploding Market 10 NGS in inherited disorders grows to a $1.5Bn market by 2020* $308m in 2015 Inherited disorders is a large healthcare problem, affecting 5% of population and driving healthcare costs. We have the best product and the lowest production cost. Inherited disorder diagnostics is a huge growth market with 38% CAGR for the next five years * Source: BCC Research, BIO126B Next-Gen Sequencing - Emerging Clinical Applications and Global Markets
  11. 11. THANK YOU! 11 Tero-Pekka Alastalo, President +1 650 285 8564 tpa@blueprintgenetics.com 953 Indiana Street, QB3@953 CA 94107 San Francisco

×